Fenwal, focused on improving blood collection, separation, safety and availability, has received the US Food and Drug Administration 510(k) clearance to market a new software release for its plasma collection system, Autopheresis-C system.

Fenwal said that the the new software includes many new features designed to improve plasma collection for plasma- and blood-center professionals and also donors.

The Autopheresis-C system helps to automate and streamline collection processes, which reduce the need for operator intervention and also helps to improve work flow and reduce procedure times and its new confirmatory prompts are designed to make accurate programming for target plasma volumes even easier.

Fenwal chief technology officer William Cork said that the Autopheresis-C system has long been an industry standard for collecting plasma of exceptional quality and the customers can expect a series of innovations from Fenwal designed to make great instruments even better in terms of speed, ease of use and communications with plasma center information systems.

Fenwal has established technical partnerships with pharmaceutical companies to assist them in this research and development.